Markers that predict response to immunotherapy before lung surgery
Part of Cancer, Lungs & breathing clinical trials.
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer in stage II to IIIB
- Your tumor testing shows EGFR is negative and ALK is negative
- You choose to join, sign consent, and agree to follow-up visits
- You have not had another cancer in the past 5 years
- You do not have an autoimmune disease that would make immune (PD-1) treatment unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial looks at how your immune system markers might help predict your outlook after lung cancer surgery. It aims to see if certain immune signals can guide future treatment planning.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.